2022

Journal Articles- Refereed

YH To, P Gibbs, J Tie, M IJzerman, K Degeling. Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review. Cost Effectiveness and Resource Allocation 21 (1), 11

YJ Kang, S O’Haire, F Franchini, M IJzerman, J Zalcberg, F Macrae, ... A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours. Scientific reports 12 (1), 20495

S O’Haire, K Degeling, F Franchini, B Tran, SJ Luen, C Gaff, K Smith, ... MJ IJzerman. Comparing survival outcomes for advanced cancer patients who received complex genomic profiling using a synthetic control arm. Targeted Oncology 17 (5), 539-548

M Vu, K Degeling, ER Thompson, P Blombery, D Westerman, MJ IJzerman. Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. European Journal of Haematology 108 (6), 469-485

J Zhang, MJ IJzerman, J Oberoi, N Karnchanachari, RJ Bergin, F Franchini, ... Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes. Lung Cancer 166, 27-39

J Zhang, P Basu, JD Emery, MJ IJzerman, F Bray. Lung cancer statistics in the United States: a reflection on the impact of cancer control. Annals of Cancer Epidemiology 6

K Degeling, MJ IJzerman, CGM Groothuis-Oudshoorn, MD Franken, ... Comparing modeling approaches for discrete event simulations with competing risks based on censored individual patient data: a simulation study and illustration in colorectal cancer. Value in health 25 (1), 104-115